This editorial refers to 'Critical role of histone demethylase Jumonji domain-containing protein 3 in the regulation of neointima formation following vascular injury' by X. Luo et al., pp. 1894 Luo et al., pp. -1906 Lysine demethylases (KDM) are epigenetic enzymes which activity is finalized to the removal of methyl groups from histone and non-histone proteins. Jumonji domain-containing protein 3 (JMJD3), is also known as lysine specific demethylase 6B (KDM6B). This is a member of the Fe(II)and a-ketoglutarate-dependent demethylases reported to activate gene expression by removing tri-methylated histone 3 lysine 27 residues (H3K27me3) enabling gene expression often in co-operation with KDM6A also referred to as X-chromosome tetratricopeptide repeat protein (UTX). 1 A role for JMJD3 during development has been established: it contributes to lung, 2 gastrointestinal tract, and endocrine glands formation. 3 It can also drive differentiation of mesenchymal stem cells 4 and regulate the expression of bone morphogenetic protein in the spinal cord. 5 During cardiac differentiation of embryonic stem cells, JMJD3 knockdown altered the formation of cardiac endothelium while in vivo the absence of JMJD3 was not compatible with survival, 6 highlighting the unicity and the importance of this epigenetic enzyme especially in early proliferative stages. JMJD3, in fact, has been found to be a Notch pathway regulator active in dividing cells such as in epidermis 7 or in stem cells reservoirs.
In cancers, Jumonji family members have been often found upregulated and their inhibition by a small molecule called JIB-04, which is pan-selective inhibitor, determined produced anticancer effects. In colorectal cancer stem cells, in fact, the inhibition of Jumonji proteins reduced cell growth and metastasis possibly by Wnt/b-catenin pathway suppression. 8 Little is known about JMJD3 involvement in cardiovascular disease. In literature, in peritoneal foam cells JMJD3 has been reported to upregulate pro-fibrotic genes demethylating H3K27me3. 9 However, in mice kept under high fat diet and with JMJD3 knockout-peritoneal foam cells, it has been demonstrated that necrosis increases, leucocyte chemotaxis genes are up-regulated, pro-fibrotic genes are repressed while in atherosclerotic lesions collagen deposition has been found higher than controls. 10 Indeed, these contradictory findings might be partly explained by the involvement of other collagen secreting cells, such as smooth muscle cells, and by the fact that peritoneal foam cells are not the only type of macrophages present in atherosclerotic lesions. Accordingly, in mice in which foam cells are deficient in JMJD3 expression, the atherosclerotic damage is more severe than in wild-type because the lesion initiate faster in association with a chemokine burst occurring in foam cells. 10 Remarkably, here, although in JMJD3 deficient foam cells there are no clearly identified candidate gene or pathway leading to an accelerated atherosclerotic lesion, the evidence suggest that JMJD3 may act as vascular protector. 10 Luo et al. 11 provides evidence in favour of a new and detrimental role for JMJD3 in neointima formation upon vascular injury. Normally, vascular smooth muscle cells (VSMCs) undergoing proliferation after damage of the intima layer, increase migration, matrix synthesis, and express less mature smooth muscle-specific genes. 12 All these changes contribute to vascular damage exacerbation leading to neointima formation.
Here, Luo et al. investigating the role of JMJD3 in neointima formation, found that in human carotid atherosclerotic plaques the expression levels of JMJD3, MMP2, MMP9, PCNA, Cyclin D1, collagen, and Nox4 were increased compared to controls. This evidence suggested for the association of JMJD3 regulatory signals with those occurring in damaged vessels and involved in cellular proliferation and extracellular matrix deposition. Similar findings were observed, in mice and rats, after intima damaging 13 provoked by partial carotid arterial ligation or carotid balloon expansion, respectively.
Interestingly, Luo et al. also provided evidence in favour of a direct action of JMJD3 at the promoter level of genes upregulated during neointima formation. JMJD3, in fact, appears contributing to their transcriptional activation (see Figure 1 ) eventually causing a detrimental effect. To functionally approach the role of this epigenetic enzyme in neointima formation, the authors silenced JMJD3, in vitro and in vivo, by means of locally applied pluronic gel embedded with specific siRNAs or by the administration of GSKJ4, a pharmacological inhibitor of JMJD3. As a result, in cells in which JMJD3 had been inhibited, proliferation markers decreased even after activation by using PDGF-BB. In vivo, cell migration from media to intima was also inhibited in spite of the injury and all downstream Nox4-dependent pathway components were suppressed. 
In conclusion, the findings from Luo et al. suggest that JMJD3 might be considered as a possible epigenetic target suitable for molecular therapies aimed to suppress VSMCs migration/proliferation and preventing neointima hyperplasia. Indeed, that of Luo et al. is a very intriguing work that provides novel perspectives; however, it must be said that much more work is required to fully understand the epigenetic control network deputed to VSMCs activation after intimal damage. In this direction, a remarkable problem may be represented by the redundancy of the epigenetic mechanisms and, planning for a therapeutic approach, by the necessity of conferring tissue selectivity to JMJD3 inhibitors aimed to arterial VSMCs suppression. Further drawbacks can arise from the administration strategy to avoid unfavourable reactions potentially arising from a systemic JMJD3 inhibition or in consequence of a difficult and invasive local application.
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